- 1.
Global Initiative for Chronic Obstructive Lung Disease. https://goldcopd.org/gold-reports/ Lest 21.8.2019.
- 2.
Johannessen A, Nilsen RM, Storebø M et al. Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med 2013; 188: 51–9. [PubMed][CrossRef]
- 3.
Kols. Nasjonal faglig retningslinje og veileder for forebygging, diagnostisering og oppfølging. Oslo: Helsedirektoratet, 2012. https://www.helsedirektoratet.no/retningslinjer/kols/Kols%20%E2%80%93%20Nasjonal%20faglig%20retningslinje%20og%20veileder%20for%20forebygging,%20diagnostisering%20og%20oppf%C3%B8lging.pdf/_/attachment/inline/e974222b-9d84-4358-84d5-9dd57b090786:ce015dd544648e3ae7bc4377269c52309a68aa77/Kols%20%E2%80%93%20Nasjonal%20faglig%20retningslinje%20og%20veileder%20for%20forebygging,%20diagnostisering%20og%20oppf%C3%B8lging.pdf Lest 21.8.2019.
- 4.
Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. Lancet 2017; 389: 1864–5. [PubMed][CrossRef]
- 5.
Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89. [PubMed][CrossRef]
- 6.
Agusti A, Fabbri LM, Singh D et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018; 52: 1801219. [PubMed][CrossRef]
- 7.
Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699–708. [PubMed][CrossRef]
- 8.
Herth FJF, Bramlage P, Müller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. Respiration 2015; 89: 66–75. [PubMed][CrossRef]
- 9.
Wang JJ, Rochtchina E, Tan AG et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 2009; 116: 652–7. [PubMed][CrossRef]
- 10.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 2014: CD010115. [PubMed]
- 11.
Crim C, Calverley PMA, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–7. [PubMed][CrossRef]
- 12.
Pavord ID, Lettis S, Locantore N et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016; 71: 118–25. [PubMed][CrossRef]
- 13.
Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract 2014; 15: 42. [PubMed][CrossRef]
- 14.
Watz H, Tetzlaff K, Wouters EFM et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390–8. [PubMed][CrossRef]
()
File
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.